

Anton J M Loonen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9547347/anton-j-m-loonen-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

78
papers

893
citations

17
h-index

25
g-index

89
ext. papers

1,170
ext. citations

3.7
avg, IF

4.78
L-index

#	Paper	IF	Citations
78	Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples.. <i>Therapeutic Advances in Psychopharmacology</i> , 2022 , 12, 20451253211065857	4.9	
77	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. <i>Genes</i> , 2022 , 13, 844	4.2	0
76	Circuits Regulating Pleasure and Happiness - Focus on Potential Biomarkers for Circuitry including the Habenuloid Complex.. <i>Acta Neuropsychiatrica</i> , 2022 , 1-36	3.9	3
75	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. <i>Human Psychopharmacology</i> , 2021 , e2826	2.3	1
74	Genetic Polymorphisms of Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
73	Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	6
72	Neurobiological mechanisms associated with antipsychotic drug-induced dystonia. <i>Journal of Psychopharmacology</i> , 2021 , 35, 3-14	4.6	5
71	Putative role of vitamin D in the mechanism of alcoholism and other addictions - a hypothesis. <i>Acta Neuropsychiatrica</i> , 2021 , 33, 1-8	3.9	1
70	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	1
69	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. <i>Frontiers in Psychiatry</i> , 2021 , 12, 661174	5	3
68	Clinical Evaluation of Different Treatment Strategies for Motor Recovery in Poststroke Rehabilitation during the First 90 Days. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
67	Search for Possible Associations of Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021 , 14, 1123-1131	2.1	1
66	A New Paradigm to Indicate Antidepressant Treatments.. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
65	Beta-Endorphin and Oxytocin in Patients with Alcohol Use Disorder and Comorbid Depression. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	2
64	P.0579 Pharmacogenetic study to elucidate putative dopaminergic mechanisms of antidepressant action. <i>European Neuropsychopharmacology</i> , 2021 , 53, S424-S425	1.2	
63	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. <i>Frontiers in Molecular Neuroscience</i> , 2020 , 13, 63	6.1	6
62	Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression. <i>Frontiers in Psychiatry</i> , 2020 , 11, 296	5	9

61	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia. <i>The Application of Clinical Genetics</i> , 2020 , 13, 97-105	3.1	2
60	Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. <i>Human Psychopharmacology</i> , 2020 , 35, e2737	2.3	1
59	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1827-1835	3.8	6
58	Association Between BDNF Gene Variant Rs6265 and the Severity of Depression in Antidepressant Treatment-Free Depressed Patients. <i>Frontiers in Psychiatry</i> , 2020 , 11, 38	5	7
57	Serum BDNF's Role as a Biomarker for Motor Training in the Context of AR-Based Rehabilitation after Ischemic Stroke. <i>Brain Sciences</i> , 2020 , 10,	3.4	9
56	P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients. <i>European Neuropsychopharmacology</i> , 2020 , 40, S331-S332 ^{1,2}		
55	Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia. <i>Metabolites</i> , 2020 , 10,	5.6	6
54	Genetic polymorphisms of PIP5K2A and course of schizophrenia. <i>BMC Medical Genetics</i> , 2020 , 21, 171	2.1	3
53	Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome. <i>Diagnostics</i> , 2020 , 10,	3.8	5
52	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of and muscarinic receptors. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 72-77	3.8	9
51	Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2020 , 16, 1051-1058	3.1	5
50	Consider Role of Glutamatergic Habenula-projecting Globus Pallidus in OCD. <i>Pharmacopsychiatry</i> , 2019 , 52, 203-204	2	3
49	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. <i>BMC Medical Genetics</i> , 2019 , 20, 47	2.1	12
48	Tardive dyskinesia in schizophrenia: Gene polymorphisms of muscarinic and adrenergic receptors. <i>European Neuropsychopharmacology</i> , 2019 , 29, S117-S118	1.2	
47	Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. <i>Heliyon</i> , 2019 , 5, e02033	3.6	18
46	Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. <i>Journal of Affective Disorders</i> , 2019 , 259, 432-439	6.6	4
45	Putative role of pharmacogenetics to elucidate the mechanism of tardive dyskinesia in schizophrenia. <i>Pharmacogenomics</i> , 2019 , 20, 1199-1223	2.6	9
44	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1462	5.6	8

43	Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. <i>Frontiers in Psychiatry</i> , 2019 , 10, 803	5	13
42	No evidence so far of a major role of AKT1 and GSK3B in the pathogenesis of antipsychotic-induced tardive dyskinesia. <i>Human Psychopharmacology</i> , 2019 , 34, e2685	2.3	4
41	Evolution of circuits regulating pleasure and happiness with the habenula in control. <i>CNS Spectrums</i> , 2019 , 24, 233-238	1.8	11
40	Circuits regulating pleasure and happiness: evolution and role in mental disorders. <i>Acta Neuropsychiatrica</i> , 2018 , 30, 29-42	3.9	22
39	The functional variant rs334558 of is associated with remission in patients with depressive disorders. <i>Pharmacogenomics and Personalized Medicine</i> , 2018 , 11, 121-126	2.1	9
38	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018 , 21, 340-346	3.4	7
37	Terug naar de basis: een andere focus bij neuro-psycho-biologisch onderzoek. <i>Neuropraxis</i> , 2018 , 22, 116-123	0	
36	Remaining Need for In Vitro Test to Elucidate 5-Hydroxytryptamine 2C Receptor Functioning. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 410-411	1.7	3
35	The evolutionary old forebrain as site of action to develop new psychotropic drugs. <i>Journal of Psychopharmacology</i> , 2018 , 32, 1277-1285	4.6	11
34	Commentary on "A non-reward attractor theory of depression": A proposal to include the habenula connection. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 83, 736-741	9	8
33	The role of the habenula in the transition from reward to misery in substance use and mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 80, 276-285	9	44
32	Biomarkers of depressive disorders: A multiplex analysis of blood serum. <i>European Psychiatry</i> , 2017 , 41, S524-S524	6	1
31	Prolactin gene polymorphism (-1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. <i>Schizophrenia Research</i> , 2017 , 182, 110-114	3.6	17
30	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017 , 18, 239-246	3.8	21
29	Predictive genetic model for levodopa-induced dyskinesia in patients with Parkinson's disease. <i>European Neuropsychopharmacology</i> , 2017 , 27, S1039-S1040	1.2	
28	Association of Polymorphisms of Serotonin Transporter (5HTTLPR) and 5-HT2C Receptor Genes with Criminal Behavior in Russian Criminal Offenders. <i>Neuropsychobiology</i> , 2017 , 75, 200-210	4	7
27	Circuits Regulating Pleasure and Happiness in Bipolar Disorder. <i>Frontiers in Neural Circuits</i> , 2017 , 11, 35	3.5	15
26	Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Clozapine. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, e1211-e1218	4.6	18

25	Circuits regulating pleasure and happiness in major depression. <i>Medical Hypotheses</i> , 2016 , 87, 14-21	3.8	45
24	Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding. <i>Parkinsons Disease</i> , 2016 , 2016, 6461907	2.6	6
23	Circuits Regulating Pleasure and Happiness-Mechanisms of Depression. <i>Frontiers in Human Neuroscience</i> , 2016 , 10, 571	3.3	38
22	Circuits Regulating Pleasure and Happiness: The Evolution of the Amygdalar-Hippocampal-Habenular Connectivity in Vertebrates. <i>Frontiers in Neuroscience</i> , 2016 , 10, 539 ^{5.1}		22
21	Circuits Regulating Pleasure and Happiness: A Focus on Addiction, Beyond the Ventral Striatum 2016 ,		5
20	Circuits Regulating Pleasure and Happiness in Schizophrenia: The Neurobiological Mechanism of Delusions 2016 ,		2
19	Likelihood of mechanistic roles for dopaminergic, serotonergic and glutamatergic receptors in tardive dyskinesia: A comparison of genetic variants in two independent patient populations. <i>SAGE Open Medicine</i> , 2016 , 4, 2050312116643673	2.4	11
18	Gene polymorphism of dopaminergic, serotonergic and glutamatergic receptors and tardive dyskinesia in schizophrenia. <i>European Neuropsychopharmacology</i> , 2016 , 26, S495-S496	1.2	
17	Circuits regulating pleasure and happiness: the evolution of reward-seeking and misery-fleeing behavioral mechanisms in vertebrates. <i>Frontiers in Neuroscience</i> , 2015 , 9, 394	5.1	51
16	Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility. <i>World Journal of Biological Psychiatry</i> , 2015 , 16, 200-5	3.8	15
15	Dehydroepiandrosterone sulphate as a putative protective factor against tardive dyskinesia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014 , 50, 172-7	5.5	9
14	No news without new scientific ideas. <i>CNS Spectrums</i> , 2014 , 19, 110-1	1.8	1
13	Association study indicates a protective role of phosphatidylinositol-4-phosphate-5-kinase against tardive dyskinesia. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	19
12	Is somatic health screening in patients with severe mental illness of added value?. <i>Perspectives in Psychiatric Care</i> , 2014 , 50, 186-92	2.2	1
11	Gaps in health care for the somatic health of outpatients with severe mental illness. <i>International Journal of Mental Health Nursing</i> , 2013 , 22, 249-55	3.8	18
10	Improvement of care for the physical health of patients with severe mental illness: a qualitative study assessing the view of patients and families. <i>BMC Health Services Research</i> , 2013 , 13, 426	2.9	28
9	New insights into the mechanism of drug-induced dyskinesia. <i>CNS Spectrums</i> , 2013 , 18, 15-20	1.8	72
8	No involvement of the adenosine A2A receptor in tardive dyskinesia in Russian psychiatric inpatients from Siberia. <i>Human Psychopharmacology</i> , 2012 , 27, 334-7	2.3	10

7	Substantial skin disorders in psychiatric illness coincide with diabetes and addiction. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 392-7	4.6	4
6	The Mechanism of Drug-induced Akathisia. <i>CNS Spectrums</i> , 2011 , 16, 7-10	1.8	26
5	Skin disorders in chronic psychiatric illness. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1151-6	4.6	17
4	Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009 , 33, 475-81	5.5	44
3	Neurobiologie van cognitieve en emotionele motivatie. <i>Neuropraxis</i> , 2006 , 10, 77-88	0	8
2	Retrospective evaluation of the effect of omeprazole on clozapine metabolism. <i>International Journal of Clinical Pharmacy</i> , 2004 , 26, 180-2		13
1	The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. <i>International Journal of Neuropsychopharmacology</i> , 2000 , 3, 285-296	5.8	21